{"id":54616,"date":"2023-03-08T10:04:51","date_gmt":"2023-03-08T09:04:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/"},"modified":"2023-03-08T10:04:51","modified_gmt":"2023-03-08T09:04:51","slug":"biocytogen-announces-renlite-licensing-agreement-with-janssen","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/","title":{"rendered":"Biocytogen Announces RenLite\u2122 Licensing Agreement with Janssen"},"content":{"rendered":"
\n

BEIJING–(BUSINESS WIRE)–#Antibody<\/a>–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (\u201cJanssen\u201d). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen\u2019s proprietary RenLite\u2122 platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.\n<\/p>\n

<\/a><\/p>\n

\nRenLite is a member of Biocytogen\u2019s fully human antibody RenMice\u2122 family. RenLite mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.\n<\/p>\n

\nDr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: \u201cWe are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.\u201d\n<\/p>\n

\nAbout RenMice<\/b>\u2122<\/a>\n<\/p>\n

\nRenMice\u2122 are Biocytogen\u2019s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab\u2122, RenLite\u2122 and RenNano\u2122 mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen\u2019s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ <\/i>replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ<\/i> to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).\n<\/p>\n

\nRenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA\/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.\n<\/p>\n

\nAs of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.\n<\/p>\n

\nAbout Biocytogen<\/b>\n<\/p>\n

\nBiocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab\u2122\/RenLite\u2122\/RenNano\u2122 mice platforms for fully human monoclonal, bispecific\/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo<\/i> drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and\/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum<\/a>. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice\u2122 licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen’s internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http:\/\/en.biocytogen.com.cn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBiocytogen<\/b>
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com<\/a>
Media: pr@bbctg.com.cn<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (\u201cJanssen\u201d). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen\u2019s proprietary RenLite\u2122 platform and underlying intellectual … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54616","6":"format-standard","7":"category-industry"},"yoast_head":"\nBiocytogen Announces RenLite\u2122 Licensing Agreement with Janssen - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Announces RenLite\u2122 Licensing Agreement with Janssen - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (\u201cJanssen\u201d). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen\u2019s proprietary RenLite\u2122 platform and underlying intellectual ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-08T09:04:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230308005303\/en\/1733117\/21\/LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Biocytogen Announces RenLite\u2122 Licensing Agreement with Janssen\",\"datePublished\":\"2023-03-08T09:04:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/\"},\"wordCount\":594,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005303\\\/en\\\/1733117\\\/21\\\/LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/\",\"name\":\"Biocytogen Announces RenLite\u2122 Licensing Agreement with Janssen - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005303\\\/en\\\/1733117\\\/21\\\/LOGO.jpg\",\"datePublished\":\"2023-03-08T09:04:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005303\\\/en\\\/1733117\\\/21\\\/LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005303\\\/en\\\/1733117\\\/21\\\/LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/biocytogen-announces-renlite-licensing-agreement-with-janssen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Announces RenLite\u2122 Licensing Agreement with Janssen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biocytogen Announces RenLite\u2122 Licensing Agreement with Janssen - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Announces RenLite\u2122 Licensing Agreement with Janssen - Pharma Trend","og_description":"BEIJING–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (\u201cJanssen\u201d). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen\u2019s proprietary RenLite\u2122 platform and underlying intellectual ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-08T09:04:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230308005303\/en\/1733117\/21\/LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Biocytogen Announces RenLite\u2122 Licensing Agreement with Janssen","datePublished":"2023-03-08T09:04:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/"},"wordCount":594,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230308005303\/en\/1733117\/21\/LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/","url":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/","name":"Biocytogen Announces RenLite\u2122 Licensing Agreement with Janssen - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230308005303\/en\/1733117\/21\/LOGO.jpg","datePublished":"2023-03-08T09:04:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230308005303\/en\/1733117\/21\/LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230308005303\/en\/1733117\/21\/LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/biocytogen-announces-renlite-licensing-agreement-with-janssen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Announces RenLite\u2122 Licensing Agreement with Janssen"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54616"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54616\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}